Replies to post #81842 on $heff's $tation of $tocks & $olid DD

[$heff]

OXGN..$2.40..financial summary here. Plenty of cash moving forward. Only 20m shares fully diluted & no debt.

[pharma_trader]

OXGN $2.45-Awesone DD Sheff, Thanks. Glad to see that direct offering was done at $2.96 and current price of $2.45 suggests this is very undervalued. And with upcoming catalysts ahead this may see major upside imo.. Also noticed about $40M cash in hand and mkt cap about 50M ? THis is insanely flying under the radar imo.

Thanks.

[$heff]

New Economy Portfolio..buying a full position in a stock that will do well into their Nov 9th Catalyst date.

Alert bought $OXGN at $2.15 in the New Economy Portfolio..Gynecologic Oncology Group (GOG) Ph.2 Ovarian Cancer Trial data will be presented Nov 9th from late Sept meeting that I had earlier.

The company has a market cap of only 39m. It has an O/S of 15.3m and a float of 13.4m. Company just did a recent financing at $2.96/share. OXGN has a 52wk low of $1.96 & a 52wk high of $5.40.
Oxigene Corporate Presentation May 2014..$OXGN http://bit.ly/1jfm32B

OXGN..Wainright assumes a buy on 6/26/14. http://www.smarteranalyst.com/2014/06/26/h-c-wainright-assumes-buy-as-oxigene-displays-tremendous-potential-upside/

OXiGENE, Inc. Announces $16 Million At-The-Market Registered Direct Offering. This offering was done at $2.96/share.
http://finance.yahoo.com/news/oxigene-inc-announces-16-million-130000685.html

@adamfeuerstein: $OXGN Surprises With Positive Ovarian Cancer Study Success —> http://t.co/67O3wta2B4

@FierceBiotech: Oxigene roars back to life on positive ovarian cancer study. http://t.co/fI9oX3ItGX

http://investorshub.advfn.com/boards/post_reply.aspx?message_id=104080522

Disclaimer: http://bit.ly/OlN9DB